Androgen deprivation therapy for prostate cancer: new concepts and concerns.
about
Androgen actions on endothelium functions and cardiovascular diseasesOptimal delivery of male breast cancer follow-up care: improving outcomesInfluence of age on incident diabetes and cardiovascular disease in prostate cancer survivors receiving androgen deprivation therapyCancer treatment-related bone disease.Gossypol induces apoptosis by activating p53 in prostate cancer cells and prostate tumor-initiating cells.Androgen Deprivation Therapy and the Re-emergence of Parenteral Estrogen in Prostate Cancer.Bone health in the prostate cancer patient receiving androgen deprivation therapy: a review of present and future management options.Androgen deprivation therapy for prostate cancer is associated with cardiovascular morbidity and mortality: a meta-analysis of population-based observational studies.Risk of colorectal cancer in men on long-term androgen deprivation therapy for prostate cancer.Radiotherapy combined with hormonal therapy in prostate cancer: the state of the art.High-dose isoflavones do not improve metabolic and inflammatory parameters in androgen-deprived men with prostate cancer.Bone complications among prostate cancer survivors: long-term follow-up from the prostate cancer outcomes study.Dose-escalated radiotherapy for high-risk prostate cancer: outcomes in modern era with short-term androgen deprivation therapy.Lack of an effect of high dose isoflavones in men with prostate cancer undergoing androgen deprivation therapy.Androgen deprivation therapy for the treatment of prostate cancer: consider both benefits and risksRisk stratification in the hormonal treatment of patients with prostate cancerClinical utility of denosumab for treatment of bone loss in men and womenSix-month gonadotropin releasing hormone (GnRH) agonist depots provide efficacy, safety, convenience, and comfort.Connecting the Lines between Hypogonadism and Atherosclerosis.Towards a diagnostic and therapeutic consensus in male osteoporosisMale osteoporosis: A reviewAdoption of Intermittent Androgen Deprivation Therapy for Advanced Prostate Cancer: A Population Based Study in American Urology Practice.Bone density testing among prostate cancer survivors treated with androgen-deprivation therapyToremifene decreases vertebral fractures in men younger than 80 years receiving androgen deprivation therapy for prostate cancerHematological changes during androgen deprivation therapyItalian association of clinical endocrinologists (AME) position statement: drug therapy of osteoporosis.Adverse effects of androgen deprivation therapy in prostate cancer: Current management issues.Oral administration of the GnRH antagonist acyline, in a GIPET-enhanced tablet form, acutely suppresses serum testosterone in normal men: single-dose pharmacokinetics and pharmacodynamicsPatient anxiety about prostate cancer independently predicts early initiation of androgen deprivation therapy for biochemical cancer recurrence in older men: a prospective cohort study.Germline genetic profiling in prostate cancer: latest developments and potential clinical applications.Denosumab: in cancer treatment-induced bone loss.Androgen regulation of prostate cancer: where are we now?Systemic bias in the medical literature on androgen deprivation therapy and its implication to clinical practice.Improving selective androgen receptor modulator discovery and preclinical evaluation.Psychological effects of androgen-deprivation therapy on men with prostate cancer and their partners.Cognitive Impacts of Estrogen Treatment in Androgen-Deprived Males: What Needs to be Resolved.Bisphosphonate related osteonecrosis of the jaws (BRONJ) in osteoporotic males.Changes in Body Image in Patients with Prostate Cancer over 2 Years of Treatment with a Gonadotropin-Releasing Hormone Analogue (Triptorelin): Results from a Belgian Non-Interventional Study.Androgen deprivation therapy in men with prostate cancer: how should the side effects be monitored and treated?Androgen deprivation therapy's impact on the mood of prostate cancer patients as perceived by patients and the partners of patients.
P2860
Q26750657-3178CB6B-C5A5-4166-9901-F440ED7FCC51Q26773195-0B4A2B1F-FD70-491D-BBC4-A9399DCE263CQ27308917-B24D0F7F-5417-4FF2-A863-9263F0CFCBADQ30438185-D603664A-EAC7-4EB3-A647-8A031A2B3DBCQ33647720-CEC0D5EF-A36F-4208-8D70-74BFED6ED428Q33736308-D6D4DB45-5131-4873-8A22-9A2BB494B993Q33754036-B8887083-7496-41AE-BBFC-22B2F02EBBADQ34267991-2D381A9B-8482-474A-B353-93F5526F2096Q34366865-2770CCCB-CEBE-4FC1-A494-7213C2CA643AQ34417815-488B1843-9C8F-483D-BEF9-C75DAA934DD2Q34420098-8D31F512-C193-4D74-BB25-445BE59DC557Q34490592-4174DB34-D268-49B3-8722-F2E08CB1397EQ34629967-2F8A29F2-2B8B-41C0-BA13-9EEAB0085E76Q34943307-D76A8CB4-100C-4742-B80F-E08646207473Q34960686-B7DB2513-0731-4402-978A-7CCF4209901DQ35076189-F04E55E0-B6D3-4231-A3CD-68D499F8F2E9Q35092799-31BB7710-9FFA-48CB-9F43-6798268F22DEQ35161023-56A22BC1-7381-4F23-A142-93E146DE80AAQ35810628-F4D72C30-3629-4D11-99DD-E9E58BD75278Q36564415-1CFBFC3A-4074-4AB5-A8A5-D2C59B741CE1Q36568540-60D74B9C-BD71-4152-877F-B1BAFA5FA8B8Q36623249-F740950E-6F42-4B49-94F6-473BD4B1A752Q36898869-2553A178-6CB8-445F-AA8E-75769AA0AAD6Q36900784-0B26016D-F04B-430A-945D-237D8813AD4EQ37074374-92A7B6D9-648A-43D5-933D-30CDAE446853Q37135281-6A485637-8220-476F-A6E2-FA77E15912B7Q37260338-AB107E2A-9C65-4635-B2EC-A5D622EA6AD4Q37291951-675B38D0-3D46-4C42-8E54-52D12DECAD82Q37334738-7D420C86-F199-48AC-ACD3-DC545CDFB383Q37474516-9779A61E-C4EC-4C03-A3B1-21B9F815D9C6Q37806196-8E904EC0-FDDD-4BEF-8072-D94C60B2E545Q37836264-51A10FA5-7ED2-4B28-9F53-9AF9931D3414Q38060823-6F890BBC-BE3A-411F-AD85-084EB5BAFD41Q38088367-BA945F6C-14AE-4D49-85E3-605E00249FC1Q38587219-B7DC21E3-3366-4B07-99C4-E4132D70A66DQ38745521-84468395-6991-47BB-855D-B37664B10A73Q39367690-8726F830-3806-4510-8E4A-4C3F4FB82151Q39615780-012B2248-97F2-4E66-BB66-7AC0FB169D86Q39815205-E5420DAF-F559-42AE-B6A1-979701EBC00BQ40582215-3EC0F0D8-DCCC-4944-8F94-A7F0CFB8BB0A
P2860
Androgen deprivation therapy for prostate cancer: new concepts and concerns.
description
2007 nî lūn-bûn
@nan
2007 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Androgen deprivation therapy for prostate cancer: new concepts and concerns.
@ast
Androgen deprivation therapy for prostate cancer: new concepts and concerns.
@en
Androgen deprivation therapy for prostate cancer: new concepts and concerns.
@nl
type
label
Androgen deprivation therapy for prostate cancer: new concepts and concerns.
@ast
Androgen deprivation therapy for prostate cancer: new concepts and concerns.
@en
Androgen deprivation therapy for prostate cancer: new concepts and concerns.
@nl
prefLabel
Androgen deprivation therapy for prostate cancer: new concepts and concerns.
@ast
Androgen deprivation therapy for prostate cancer: new concepts and concerns.
@en
Androgen deprivation therapy for prostate cancer: new concepts and concerns.
@nl
P2860
P1476
Androgen deprivation therapy for prostate cancer: new concepts and concerns.
@en
P2093
Matthew R Smith
P2860
P304
P356
10.1097/MED.0B013E32814DB88C
P577
2007-06-01T00:00:00Z